Sigfredo Romero, Unit Coordinator at GenesisCare in Spain, shared a post on LinkedIn:
“ASTRO 2025 | Stereotactic Radiotherapy in 3 Fractions for Localized Prostate Cancer.
The Italian group (Sanguineti et al.) presented the outcomes of an ultra-hypofractionated regimen of 40 Gy in 3 fractions (EOD) for patients with low- and favorable-intermediate–risk prostate cancer.
Population: 159 patients
Median follow-up: 59.8 months
Key Results
Oncological control: excellent, with only 4 documented failures
Late toxicity:
• Genitourinary G2 in 10.7%, no G3+
• Gastrointestinal G2–3 in 3.8%
Quality of life:
• Urinary symptoms (IPSS) improved significantly and remained stable
• Sexual function (IIEF-5) showed a gradual decline, with partial preservation in some patients
Authors’ conclusion:
Stereotactic radiotherapy with 40 Gy in 3 fractions is highly effective and well tolerated in patients with localized prostate cancer (low to favorable-intermediate risk).
Another step forward toward shorter, safe, and effective treatment schedules in prostate cancer radiotherapy.”
Read more posts about Radiotherapy on OncoDaily.
